<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614064</url>
  </required_header>
  <id_info>
    <org_study_id>20SM6236</org_study_id>
    <nct_id>NCT04614064</nct_id>
  </id_info>
  <brief_title>London Underground Study - Health Effects of Particulate Matter</brief_title>
  <official_title>Exposure to Particulate Matter on the London Underground in Healthy Subjects and Patients With Chronic Respiratory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An average of 4.8 million journeys are made on the London Underground every day and as the&#xD;
      'Tube' has elevated airborne particulate matter concentrations compared to ambient air, this&#xD;
      raises concern about the potential health impact of this environment. This study explores the&#xD;
      health effects of particulate matter from the London Underground on patients with COPD and&#xD;
      healthy volunteers.&#xD;
&#xD;
      Patients with COPD and healthy participants will be invited to undertake a set 90 min journey&#xD;
      on the London Underground, and on a separate occasion (3-8 weeks apart), a 90 min journey on&#xD;
      the London Overground (as a proxy for a clean air London area while maintaining other aspects&#xD;
      of a train journey). A series of clinical, physiological and inflammatory data will be&#xD;
      collected before, during and after (at different time points) each of the sessions in order&#xD;
      to compare their response in relation to exposure and/or to disease status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">October 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference (London Underground vs control exposure) in post exposure pulse wave velocity in healthy vs COPD participants.</measure>
    <time_frame>-2 hours, +2 hours, +5 hours, +6 hours, +24 hours</time_frame>
    <description>Measurement of arterial stiffness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other clinical responses on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, 0 hours, +45 minutes +90 minutes, +4 hours, +5 hours, +6 hours, +24 hours</time_frame>
    <description>Symptom questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical responses on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours</time_frame>
    <description>Spirometry (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical responses on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours</time_frame>
    <description>Spirometry (FVC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical responses on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, 0 hours, +45 minutes, +90 minutes, +2 hours, +4 hours, +6 hours, +24 hours</time_frame>
    <description>Spirometry (FEF 25-75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other clinical responses on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Single breath transfer factor for carbon monoxide (TLCO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (IL8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (High sensitivity CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (FBC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (TNFa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (vWf antigen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (Thrombin generation (systemic inflammatory response))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (8-isoprostanes (ELISA))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (Blood malondialdehyde (lipid peroxidation))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Blood sample (Oxidation Reduction Potential (oxidative stress))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (IL-8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (IL-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (IL-33)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (Myeloperoxidase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (Neutrophil lipocalin-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (Tryptases)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (Complement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (vWf antigen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (Thrombin generation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasosorption (D-dimer activation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +7 hours, +24 hours</time_frame>
    <description>Nasal curettage (mRNA levels to elucidate molecular mechanisms that may explain the toxic effects of particulate matter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +24 hours</time_frame>
    <description>Urine (8-isoprostane)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammatory and oxidative responses after the exposure on the London Underground vs control exposure</measure>
    <time_frame>-2 hours, +24 hours</time_frame>
    <description>Urine (8-hydroxy 2-deoxyguanosine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As per inclusion and exclusion criteria for COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As per inclusion and exclusion criteria for healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure to London Underground ambient particulate matter</intervention_name>
    <description>Exposure to particulate matter on the London Underground</description>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure to London air ambient particulate matter</intervention_name>
    <description>Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)</description>
    <arm_group_label>COPD patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for both groups:&#xD;
&#xD;
          -  Give informed consent&#xD;
&#xD;
          -  London resident&#xD;
&#xD;
        For participants with COPD:&#xD;
&#xD;
          -  GOLD stage 2 COPD (FEV1/FVC&lt;70%; 50%&gt;FEV1&lt;80% predicted) and GOLD stage 3 COPD&#xD;
             (FEV1/FVC&lt;70%; 30%&gt;FEV1&lt;50).&#xD;
&#xD;
          -  No history of ischaemic heart disease&#xD;
&#xD;
        For healthy volunteers:&#xD;
&#xD;
          -  No history of ischaemic heart disease.&#xD;
&#xD;
          -  Normal lung function with no evidence of airflow obstruction.&#xD;
&#xD;
        Exclusion Criteria for both participants with COPD and healthy volunteers:&#xD;
&#xD;
          -  Those with unstable ischaemic heart disease or COPD.&#xD;
&#xD;
          -  Current smokers and those who are ex-smokers of &lt;12 months duration.&#xD;
&#xD;
          -  Those who work in the London Underground or are occupationally exposed to - - high&#xD;
             levels of vehicle traffic exposure on a frequent basis.&#xD;
&#xD;
          -  Those who cannot walk for 30 mins.&#xD;
&#xD;
          -  Those with hay fever.&#xD;
&#xD;
          -  Involvement in another research study&#xD;
&#xD;
          -  Those unable to give consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Kelly</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alison Kent</last_name>
    <phone>02033126666</phone>
    <email>aek07@ic.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rudy Sinharay</last_name>
    <email>rudy.sinharay1@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Kent</last_name>
      <phone>020 3313 8070</phone>
      <email>alison.kent4@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Sinharay R, Gong J, Barratt B, Ohman-Strickland P, Ernst S, Kelly FJ, Zhang JJ, Collins P, Cullinan P, Chung KF. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet. 2018 Jan 27;391(10118):339-349. doi: 10.1016/S0140-6736(17)32643-0. Epub 2017 Dec 5. Erratum in: Lancet. 2018 Jan 27;391(10118):308.</citation>
    <PMID>29221643</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Particulate matter</keyword>
  <keyword>London Underground</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

